CD133 Is Not Suitable Marker for Isolating Melanoma Stem Cells from D10 Cell Line

被引:0
|
作者
Fomeshi, Motahareh Rajabi [1 ,2 ]
Ebrahimi, Marzieh [2 ]
Mowla, Seyed Javad [3 ]
Firouzi, Javad [2 ]
Khosravani, Pardis [2 ]
机构
[1] Univ Sci & Culture, ACECR, Dept Dev Biol, Tehran, Iran
[2] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Tehran, Iran
[3] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran
关键词
Melanoma; Cancer Stem Cell; CD133; Spheroid; HUMAN-MALIGNANT MELANOMA; IN-VITRO; CANCER; APOPTOSIS; ABCG2;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: Cutaneous melanoma is the most hazardous malignancy of skin cancer with a high mortality rate. It has been reported that cancer stem cells (CSCs) are responsible for malignancy in most of cancers including melanoma. The aim of this study is to compare two common methods for melanoma stem cell enriching; isolating based on the CD133 cell surface marker and spheroid cell culture. Materials and Methods: In this experimental study, melanoma stem cells were enriched by fluorescence activated cell sorting (FACS) based on the CD133 protein expression and spheroid culture of D10 melanoma cell line,. To determine stemness features, the mRNA expression analysis of ABCG2, c-MYC, NESTIN, OCT4-A and -B genes as well as colony and spheroid formation assays were utilized in unsorted CD133(+), CD133(-) and spheroid cells. Significant differences of the two experimental groups were compared using student's t tests and a two-tailed value of P<0.05 was statistically considered as a significant threshold. Results: Our results demonstrated that spheroid cells had more colony and spheroid forming ability, rather than CD133(+) cells and the other groups. Moreover, melanospheres expressed higher mRNA expression level of ABCG2, c-MYC, NESTIN and OCT4-A compared to other groups (P<0.05). Conclusion: Although CD133(+) derived melanoma cells represented stemness features, our findings demonstrated that spheroid culture could be more effective method to enrich melanoma stem cells.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 50 条
  • [21] Expression Patterns of Thymosin β4 and Cancer Stem Cell Marker CD133 in Ovarian Cancers
    Ji, Yong-Il
    Lee, Bo-Young
    Kang, Yun-Jeong
    Jo, Jin-Ok
    Lee, Sang Ho
    Kim, Heung Yeol
    Kim, Young-Ok
    Lee, Chulmin
    Koh, Suk Bong
    Kim, Ari
    Lee, Ji Young
    Jung, Min Hyung
    Ock, Mee Sun
    Cha, Hee-Jae
    PATHOLOGY & ONCOLOGY RESEARCH, 2013, 19 (02) : 237 - 245
  • [22] Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions
    Lathia, J. D.
    Hitomi, M.
    Gallagher, J.
    Gadani, S. P.
    Adkins, J.
    Vasanji, A.
    Liu, L.
    Eyler, C. E.
    Heddleston, J. M.
    Wu, Q.
    Minhas, S.
    Soeda, A.
    Hoeppner, D. J.
    Ravin, R.
    McKay, R. D. G.
    McLendon, R. E.
    Corbeil, D.
    Chenn, A.
    Hjelmeland, A. B.
    Park, D. M.
    Rich, J. N.
    CELL DEATH & DISEASE, 2011, 2 : e200 - e200
  • [23] Prominin-1 (CD133) Expression in the Prostate and Prostate Cancer: A Marker for Quiescent Stem Cells
    Pellacani, Davide
    Oldridge, Emma E.
    Collins, Anne T.
    Maitland, Norman J.
    PROMININ-1 (CD133): NEW INSIGHTS ON STEM & CANCER STEM CELL BIOLOGY, 2013, 777 : 167 - 184
  • [24] Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer
    Joseph, Chitra
    Arshad, Maariya
    Kurozomi, Sasagu
    Althobiti, Maryam
    Miligy, Islam M.
    Al-izzi, Sara
    Toss, Michael S.
    Goh, Fang Qin
    Johnston, Simon J.
    Martin, Stewart G.
    Ellis, Ian O.
    Mongan, Nigel P.
    Green, Andrew R.
    Rakha, Emad A.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (02) : 387 - 399
  • [25] Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer
    Chitra Joseph
    Maariya Arshad
    Sasagu Kurozomi
    Maryam Althobiti
    Islam M. Miligy
    Sara Al-izzi
    Michael S. Toss
    Fang Qin Goh
    Simon J. Johnston
    Stewart G. Martin
    Ian O. Ellis
    Nigel P. Mongan
    Andrew R. Green
    Emad A. Rakha
    Breast Cancer Research and Treatment, 2019, 174 : 387 - 399
  • [26] Employing CRISPR-Cas9 to Generate CD133 Synthetic Lethal Melanoma Stem Cells
    Simbulan-Rosenthal, Cynthia M.
    Haribabu, Yogameenakshi
    Vakili, Sahar
    Kuo, Li-Wei
    Clark, Havens
    Dougherty, Ryan
    Alobaidi, Ryyan
    Carney, Bonnie
    Sykora, Peter
    Rosenthal, Dean S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (04)
  • [27] Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
    Welte, Yvonne
    Davies, Cathrin
    Schaefer, Reinhold
    Regenbrecht, Christian R. A.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2013, (73):
  • [28] Pluripotent lineage of CD133 stem cells isolated from human skin samples
    Balaji, Avvari Bhaskara
    Jamil, Kaiser
    Ram, Gangaraju Maruthi
    Raju, G. Suryanarayana
    INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, 2013, 51 (02) : 107 - 115
  • [29] Finding markers for cancer stem cells in renal cell carcinoma: Looking beyond CD133
    Ottaiano, Alessandro
    CELL CYCLE, 2010, 9 (22) : 4431 - 4431
  • [30] p53 positively regulates the expression of cancer stem cell marker CD133 in HCT116 colon cancer cells
    Chen, Xia
    Guan, Hua
    Liu, Xiao-Dan
    Xie, Da-Fei
    Wang, Yu
    Ma, Teng
    Huang, Bo
    Zhou, Ping-Kun
    ONCOLOGY LETTERS, 2018, 16 (01) : 431 - 438